Recent News
Breaking World Pharma News
FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors
Roche
17 April 2018
Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra® (emicizumab-kxwh) for people with haemophilia A without factor VIII inhibitors. Breakthrough Therapy Designation is designed to accelerate the development and review of medicines intended to treat a serious condition with preliminary evidence that indicates they may demonstrate a substantial improvement over existing therapies.Read more …
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
17 April 2018
Novartis
Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting. Further, the company releases new African research on progress and remaining challenges toward the 2030 malaria elimination targets, together with Elimination 8 and the KEMRI-Wellcome Trust program.Read more …
Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford
16 April 2018
Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) have announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with established chronic kidney disease with and without diabetes.Read more …
Bristol-Myers Squibb announces worldwide collaboration with Janssen to develop and commercialize next-generation cardiovascular therapy
16 April 2018
Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today announced a worldwide collaboration with Janssen Pharmaceuticals, Inc. (Janssen) on a Factor XIa (FXIa) inhibitor program that includes the development and commercialization of Bristol-Myers Squibb’s Factor XIa (FXIa) inhibitor, BMS-986177, an investigational anticoagulant compound being studied for prevention and treatment of major thrombotic conditions.Read more …
GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
13 April 2018
GlaxoSmithKline
GSK and Orchard Therapeutics have announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients. This acquisition strengthens Orchard’s position as a global leader in gene therapy for rare diseases.Read more …
Bristol-Myers Squibb and Harvard announce new fibrosis research collaboration
12 April 2018
Bristol-Myers Squibb
Bristol-Myers Squibb Company and the Harvard Fibrosis Network of the Harvard Stem Cell Institute today announce a research collaboration to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart. The Harvard Fibrosis Network brings together researchers across the schools and affiliated hospitals of Harvard University.Read more …
Personalized tumor vaccine shows promise in pilot trial
12 April 2018
A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania. The personalized vaccine is made from patients’ own immune cells, which are exposed in the laboratory to the contents of the patients’ tumor cells, and then injected into the patients to initiate a wider immune response.Read more …
SMi presents the 2nd annual conference on Pharmaceutical Microbiology West Coast
11 April 2018
SMi Group
7 – 8 June 2018, San Diego, USA.
SMi proudly presents the 2nd Annual Pharmaceutical Microbiology West Coast Conference, in San Diego, USA. The pharmaceutical microbiology field is an ever changing in almost all areas of pharmaceuticals. Therefore, professionals within the field need to be informed and updated on the revised regulations and newly emerging methods and practices.Read more …
FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems
11 April 2018
FDA
The U.S. Food and Drug Administration today permitted marketing of the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes. Diabetic retinopathy occurs when high levels of blood sugar lead to damage in the blood vessels of the retina, the light-sensitive tissue in the back of the eye.Read more …
New class of drugs could help tackle treatment-resistant cancers
10 April 2018
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies. The drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.Read more …
Check out our latest video
Exploring our target industries
At Davalyn, our tenured team of niche-focused talent acquisition experts takes on the hiring challenges of a diverse and growing set of industries. Make our perspectives your most powerful recruitment and retention resource.
